SOPHiA GENETICS, Complete Genomics Unite for Precision Medicine
Complete Genomics, a number one innovator in genomic sequencing, right this moment introduced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a worldwide chief in AI-driven precision medication, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM on Complete Genomics’ DNBSEQ-T1+ sequencing platform. The firms purpose to broaden entry to precision oncology testing by providing the best-in-class…
